Inhibitex to Present at the Cowen and Company 31st Annual Health Care Conference
March 02 2011 - 12:06PM
Business Wire
Inhibitex, Inc. (Nasdaq: INHX), today announced that Russell
Plumb, president and chief executive officer, will present an
overview of the Company and an update of its pipeline of
differentiated anti-infective compounds at the Cowen and Company
31st Annual Health Care Conference on March 7, 2011 at 1:00 PM
(EST). The conference is being held at The Boston Marriott Copley
Place in Boston, MA. The presentation will be simultaneously
webcast and can be accessed by visiting the Investors section of
the Inhibitex website at www.inhibitex.com. Shortly following
the live webcast, a replay will also be available on the Company
website.
About Inhibitex
Inhibitex, Inc. is a biopharmaceutical company focused on
developing products to prevent and treat serious infectious
diseases. The Company’s clinical-stage pipeline includes FV-100, a
nucleoside inhibitor in Phase II for the treatment of shingles, and
INX-189, a nucleotide polymerase inhibitor in Phase 1b for the
treatment of chronic hepatitis C infections. The Company also has
additional HCV nucleotide polymerase inhibitors in preclinical
development and has licensed the use of its proprietary MSCRAMM®
protein platform to Pfizer for the development of a staphylococcal
vaccine, which is currently being evaluated in a Phase 1 clinical
trial. For additional information about the Company, please visit
www.inhibitex.com.
Inhibitex® and MSCRAMM® are registered trademarks of Inhibitex,
Inc.
Inhibitex, Inc. (MM) (NASDAQ:INHX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Inhibitex, Inc. (MM) (NASDAQ:INHX)
Historical Stock Chart
From Jul 2023 to Jul 2024